

Impact of demographic factors on clinical outcomes of patients with acute myeloid leukemia

Authors

Cassandra Duarte,^{1*} Diana Abbott,^{2*} Grace Bosma,² Andrew Kent,¹ Marc Schwartz,¹ Cailin Collins,¹ Mathew G. Angelos,¹ Christine McMahon,¹ Jonathon Gutman,¹ Daniel A. Pollyea¹ and Maria L. Amaya^{1,3}

¹Division of Hematology, Department of Medicine, The University of Colorado School of Medicine; ²Center for Innovative Design and Analysis, Department of Biostatistics and Informatics, University of Colorado Anschutz and ³Division of Hematology and Oncology, Department of Medicine, Rocky Mountain Regional VA, Aurora, CO, USA

**CD and DA contributed equally as first authors.*

Correspondence:

M. AMAYA - maria.l.amaya@cuanschutz.edu

<https://doi.org/10.3324/haematol.2025.288131>

Received: April 29, 2025.

Accepted: September 1, 2025.

Early view: September 11, 2025.

©2026 Ferrata Storti Foundation

Published under a CC BY-NC license 

Supplemental Figures and Tables

Supplementary Table 1. Classification of 1L Treatments

1L Treatment Categorization	Examples of Treatments
HMA	Azacitidine, Decitabine
7+3	7+3, CPX351
Clinical Trial	Clinical study drug used in treatment per Flatiron Health
Novel AML Therapy	Venetoclax, gemtuzumab ozogamicin, midostaurin, gilteritinib, ivosidenib, enasidenib, glasdegib
Other	Cyclophosphamide, bosutinib, dasatinib, single agent hydroxyurea, retinoin, sorafenib, ruxolitinib, lenalidomide

Supplementary Table 2. Median OS by Demographic Characteristics

Characteristic	Study Population Median OS (95% CI) P value	Age 18-39 Median OS (95% CI) P value	Age 40-59 Median OS (95% CI) P value	Age ≥ 60 Median OS (95% CI) P value
<u>Race</u> Asian Black White Other	21.4 months (12.6, 23) 18.4 months (15, 24) 16.1 months (14.9, 17.1) 15.4 months (13.6, 18.2) P = 0.6686	28.1 months, (2.3, NR) 33.5 months (20.8, 57.4) NR (65.3, NR) 52.8 months (20.7, NR) P = 0.0612	22.6 months (13.7, NR) 31.9 months (20.6, 101.6) 49.6 months (28.3, 74.6) 30 months (22.2, 52.6) P = 0.8165	12.2 months (6.5, 17.4) 12.5 months (9.8, 14.9) 12.3 months (11.2, 12.6) 12.2 months (9.9, 14.8) P = 0.6649
<u>Ethnicity</u> Hispanic/Latino Non- Hispanic/Latino	22.7 months (17.4, 35.9) 15.2 months (14.4, 16.4) P = 0.001	NR (26.7, NR) 90.3 months (45.9, NR) P = 0.8286	28.5 months (17.4, 98) 34.2 months (26.3, 52.7) P = 0.7364	16.8 months (12.5, 20.1) 11.7 months (10.8, 12.5) P = 0.0847
<u>Sex</u> Male Female	15 months (13.8, 16.1) 17.7 months (15.6, 19.3) P < 0.0001	65.3 months (38.5, NR) 90.3 months (51.9, NR) P = 0.5038	31.2 months (22.7, 48.8) 48.9 months (28.5, 73) P = 0.0610	11.4 months (10.4, 12.5) 12.4 months (11.6, 13.5) P = 0.0162
<u>SES Quintile</u> Low SES (1 + 2) High SES (4 + 5)	16.1 months (14, 18) 17.2 months (15.7, 18.6) P = 0.0311	52.8 months (31, NR) NR (52.2, NR) P = 0.1967	35.3 months (23.2, 57.9) 51.9 months (27.7, 92.2) P = 0.1699	10.8 months (9.4, 12) 13.3 months (12.1, 14.5) P = 0.0009

Supplementary Table 3. Rates of Post-2017 Treatments by SES.

Therapy	Low SES (1/2)	High SES (4/5)	P-value
Induction chemotherapy (7+3)	43%	35.7%	0.0013
Novel AML Agents (TKI, HMA/Venetoclax etc)	24%	28.3%	0.0553
Single Agent HMA	17.3%	17.5%	0.9530
Clinical Trials	5.2%	8.2%	0.0181
Transplant	18.5%	27.7%	< 0.0001